Cardiac magnetic resonance assessment of right ventricular remodeling after anthracycline therapy

Author(s):Show less -

de Souza, Thiago Ferreira ^[1] ; Silva, Thiago Quinaglia ^[1] ; Antunes-Correa, Ligia ^[1] ; Drobni, Zsofia D. ^[2] ; Costa, Felipe Osorio ^[1] ; Dertkigil, Sergio San Juan ^[1] ; Nadruz, Wilson ^[1] ; Brenelli, Facricio ^[1] ; Sposito, Andrei C. ^[1] ; Matos-Souza Jr, Jose Roberto ; Coelho, Otavio Rizzi ^[3] ; Neilan, Tomas G. ^[2] ; Jerosch-Herold, Michael ^{[4, 5]} ; Coelho-Filho, Otavio Rizzi ^[3]

Affiliation

^[1] Univ Estadual Campinas, Div Cardiol, Dept Med, Fac Ciencias Med, UNICAMP, Rua Tessalia Viera Camargo 126, BR-13083887 Campinas, SP - Brazil

^[2] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02114 - USA

^[3] Matos-Souza Jr, Jr., Jose Roberto, Univ Estadual Campinas, Div Cardiol, Dept Med, Fac Ciencias Med, UNICAMP, Rua Tessalia Viera Camargo 126, BR-13083887 Campinas, SP - Brazil

^[4] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 - USA

^[5] Brigham & Womens Hosp, Noninvas Cardiovasc Imaging Program, 75 Francis St, Boston, MA 02115 - USA

• Document type: Journal article
• Source: SCIENTIFIC REPORTS; v. 11, n. 1 AUG 24 2021.
• Web of Science Citations: 0

Abstract

There are limited data on the effects of anthracyclines on right ventricular (RV) structure, function, and tissue characteristics. The goal of this study was to investigate the effects of anthracyclines on the RV using cardiac magnetic resonance (CMR). This was a post-hoc analysis of a prospective study of 27 breast cancer (BC) patients (51.8 +/- 8.9 years) using CMR prior, and up to 3-times after anthracyclines (240 mg/m(2)) to measure RV volumes and mass, RV extracellular volume (ECV) and cardiomyocyte mass (CM). Before anthracyclines, LVEF (69.4 +/- 3.6%) and RVEF (55.6 +/- 9%) were normal. The median follow-up after anthracyclines was 399 days (IQR 310-517). The RVEF reached its nadir (46.3 +/- 6.8%) after 9-months (P < 0.001). RV mass-index and RV CM decreased to 13 +/- 2.8 g/m(2) and 8.13 +/- 2 g/m(2), respectively, at 16-months after anthracyclines. The RV ECV expanded from 0.26 +/- 0.07 by 0.14 (53%) to 0.40 +/- 0.1 (P < 0.001). The RV ECV expansion correlated with a decrease in RV mass-index (r = -0.46; P < 0.001) and the increase in CK-MB. An RV ESV index at baseline above its median predicted an increased risk of LV dysfunction post-anthracyclines. In BC patients treated with anthracyclines, RV atrophy, systolic dysfunction, and a parallel increase of diffuse interstitial fibrosis indicate a cardiotoxic response on a similar scale as previously seen in the systemic left ventricle. (AU)

• FAPESP's process: 16/26209-1 - Multi-user equipament approved in grat 2015/15402-2: cardiorespiratory diagnostic system
• Grantee: Otávio Rizzi Coelho-Filho
• Support Opportunities: Multi-user Equipment Program
• FAPESP's process: 15/15402-2 - Characterization of interstitial fibrosis and cardiomyocyte hypertrophy by cardiac MRI: implication on early remodeling and on the transition to heart failure
• Grantee: Otávio Rizzi Coelho-Filho
• Support Opportunities: Research Grants - Young Investigators Grants
• FAPESP's process: 17/03708-5 - Multi-user equipament approved in the grant 2015/15402-2: ecocardiograma
• Grantee: Otávio Rizzi Coelho-Filho
• Support Opportunities: Multi-user Equipment Program